Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Outside clinical trial related expenses Outside Clinical Trial Related Expenses Amount of outside clinical trial related expenses. Statistical Measurement [Domain] Statistical Measurement [Domain] Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Offering period Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period Represents the offering period for awards under the equity-based compensation plan. Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Accrued interest Line of Credit Facility, Increase, Accrued Interest Purchases of short-term investments Payments to Acquire Short-Term Investments Accounts payable Increase (Decrease) in Accounts Payable SOFR Secured Overnight Financing Rate (SOFR) [Member] Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Schedule of Future Minimum Payments Schedule of Line of Credit Facilities [Table Text Block] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance US treasury bills US Treasury Bill Securities [Member] Revenues Revenue from Contract with Customer [Text Block] Schedule of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Schedule of Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalent, and Investment [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Principal outstanding, net of unamortized debt issuance costs Debt Principal Outstanding, Net Of Unamortized Debt Issuance Costs Amount, after deduction of unamortized debt issuance costs. Percentage Concentration Risk, Percentage Kissei Kissei Pharmaceutical Co. Ltd. [Member] Represents Kissei Pharmaceutical Co., Ltd. Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Revenue recognized Collaborative Arrangement Revenue Recognized Represents the revenue recognized during the period under the terms of sponsored research and license agreements. FDA approval and first commercial sale of product FDA Approval And First Commercial Sale Of Product [Member] Represents FDA approval and first commercial sale of the product. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Cash, Cash Equivalents, Restricted Cash, and Short-Term Investments Cash, Cash Equivalent, and Short-Term Investment [Text Block] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Current assets: Assets, Current [Abstract] Total liabilities and stockholders’ equity Liabilities and Equity Antidilutive securities excluded from the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Maximum [Member] Maximum [Member] Commercial milestones SpecifiedCommercialMilestones [Member] Represents specified commercial milestones. Accounting Policies [Abstract] Accounting Policies [Abstract] Intangible assets, net Finite-Lived Intangible Assets, Net Prepaid research and development costs Prepaid Research And Development Costs Amount of asset related to consideration paid in advance for research and development costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount In-licensing and Acquisition Business Combination [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Final payment fee, percentage of principal Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Contractual obligations not included in financial statements Off Balance Sheet Contractual Obligations Subject To Cancellation Fees Amount of off-balance sheet contractual obligations subject to cancellation fees. Upfront fee Collaborative Arrangement Upfront Payment Amount of collaborative arrangement upfront payment. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Upfront payment received Collaborative Arrangement Upfront Fee Received Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement. Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net amortization of discount on short-term investments and term loans Investment Income, Net, Amortization of Discount and Premium Lease liabilities, current portion Operating Lease, Liability, Current Document Fiscal Period Focus Document Fiscal Period Focus Intangible assets, net Intangible Assets, Net (Including Goodwill) Award Timing Method Award Timing Method [Text Block] Schedule of Cash Equivalents and Short-Term Investments Including Securities With Unrealized Gains and Losses Unrealized Gain (Loss) on Investments [Table Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Award Type Award Type [Axis] Principal amount (Tranches 1, 2, 3 and 4) Long-Term Debt Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year One Trading Symbol Trading Symbol Issuance of common stock upon exercise of options (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, City or Town Entity Address, City or Town Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Other segment items Segment Reporting, Other Segment Item, Amount Estimated useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Concentration Risk Type [Axis] Concentration Risk Type [Axis] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] RSUs Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Four Entity Emerging Growth Company Entity Emerging Growth Company Research and development Research and Development Expense (Excluding Acquired in Process Cost) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash, Cash Equivalents, and Short-Term Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Increase in right-of-use assets and lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Unamortized debt issuance costs Debt Issuance Costs, Net Level 2 Fair Value, Inputs, Level 2 [Member] Central Nervous System, Product-by-product Sales Milestone Central Nervous System, Product-by-product Sales Milestone [Member] Central Nervous System, Product-by-product Sales Milestone Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Forma FormaTherapeuticsHoldingsInc [Member] Represents Forma Therapeutics Holdings, Inc. Allowance SEC Schedule, 12-09, Allowance, Credit Loss [Member] Schedule of Provision for Income Tax Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] PEO PEO [Member] Schedule of Revenues Disaggregated by Category Disaggregation of Revenue [Table Text Block] Optime Care, Inc. OptimeCareInc [Member] Represents Optime Care, Inc. Interest income Investment Income, Interest United States UNITED STATES Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Blueprint BlueprintMedicinesCorporation [Member] Represents Blueprint Medicines Corporation. Schedule of Estimated Future Amortization Expense of Intangible Asset Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accumulated Deficit Retained Earnings [Member] Prepaid and other current assets Total prepaid and other current assets Prepaid Expense and Other Assets, Current Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Achievement Of Milestone [Domain] Achievement Of Milestone [Domain] Different categories of achievement of milestones. Amount due to collaboration partner Due To Collaboration Partner Amount due to collaboration partner. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Provision for income taxes Income Tax Expense (Benefit) Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Fair Value Investments, Fair Value Disclosure Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Potential milestone payments Potential Milestone Payment Obligations Amount of potential milestone payment obligations. Customer concentration risk Customer Concentration Risk [Member] Cash, cash equivalents, and short-term investments Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Revenue reserves and refund liability Contract with Customer, Refund Liability, Current City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] RSUs outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Stock Options and RSUs ShareBasedCompensationOptionsAndRsus [Member] Represents share based compensation options and RSUs. First commercial sale First commercial sale [Member] Represents first commercial sale. Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Unrecognized stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Subsequent Event Subsequent Event [Member] Schedule of Weighted-Average Assumptions Relating to Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Interest expense, net Interest Income (Expense), Operating Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Money market funds Money Market Funds [Member] Remainder of 2026 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Acquisition-related liabilities Liabilities Assumed EPS Denominator-Diluted: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Equity Components [Axis] Equity Components [Axis] Payment of cost share to collaboration partner Payment Of Cost Share To Collaboration Partner Payment of cost share to collaboration partner. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Central Nervous System, Specified Development And Regulatory Milestone Non-Central Nervous System, Specified Development And Regulatory Milestone [Member] Non-Central Nervous System, Specified Development And Regulatory Milestone Product sales, net Product [Member] Number of segments Number of Reportable Segments Total Loans Payable Weighted-average assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Company's percentage of development costs Development Costs Cost Sharing Arrangement Percentage Percentage of development costs in cost sharing arrangement. Commercial related expenses Commercial Related Expenses Amount of commercial related expenses. Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Entity Address, State or Province Entity Address, State or Province Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Individual: Individual [Axis] Restricted cash reported within other assets Restricted Cash Vesting [Axis] Vesting [Axis] EPS Numerator: Earnings Per Share Reconciliation [Abstract] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Others Other Assets, Current Research and development Research and Development Expense [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity [Domain] Entity [Domain] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Grifols GrifolsS.a. [Member] Represents Grifols, S.A. Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Operating lease expense Operating Lease, Cost Weighted-average recognition period of unrecognized compensation cost (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Liquidity Liquidity And Capital Resources [Policy Text Block] Disclosure of accounting policy for liquidity and capital resources. Stock options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Gross product sales Gross Product [Member] Represents gross product. Schedule of Cash and Cash Equivalents and Available For Sale Securities [Line Items] Schedule of Cash and Cash Equivalents and Available For Sale Securities [Line Items] Schedule of Cash and Cash Equivalents and Available For Sale Securities Segment Information Segment Reporting Disclosure [Text Block] Fair Value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Delivery of drug supplies, royalties and others Royalty Delivery Of Drug Supplies And Others [Member] Royalty Delivery Of Drug Supplies And Others Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortization expense Amortization of Intangible Assets Selling, general and administrative Selling, General and Administrative Expense Headquarters office space sublease, South San Francisco, California Headquarters office space sublease, South San Francisco, California [Member] Represents Headquarters office space sublease in South San Francisco, California. Beginning Balance Ending Balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Deferred income tax asset Deferred Income Tax Assets, Net Acquisition payment Payments to Acquire Productive Assets Depreciation and amortization Depreciation, Depletion and Amortization Other assets Other Assets, Noncurrent Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Finished goods Inventory, Finished Goods, Gross Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount SPONSORED RESEARCH AND LICENSE AGREEMENTS Sponsored Research and License Agreements [Abstract] Corporate Collaborations Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Achievement of Corporate Milestones Share-Based Payment Arrangement, Tranche One [Member] McKesson Corporation MckessonSpecialtyCareDistributionCorporation [Member] Represents McKesson Specialty Care Distribution Corporation. Segments [Axis] Segments [Axis] Prepaid and other current and non-current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Unrecognized compensation cost related to purchase plan Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Assets Assets [Abstract] Credit Facility [Axis] Credit Facility [Axis] Maturities of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Underlying Security Market Price Change Underlying Security Market Price Change, Percent 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Three Vesting [Domain] Vesting [Domain] Fair Value Fair Value Disclosures [Text Block] Achievement of Milestone [Axis] Achievement of Milestone [Axis] Information by categories of milestones achieved. Credit Facility [Domain] Credit Facility [Domain] Intangible assets cost Finite-Lived Intangible Assets, Gross Stockholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Entity Address, Address Line One Entity Address, Address Line One Research and development Research and Development Expense Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Floor rate Debt Instrument, Interest Rate, Stated Percentage Investments [Domain] Investments [Domain] Shares withheld (in shares) Shares withheld (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Long-term portion of lease liabilities Operating Lease, Liability, Noncurrent Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Regulatory milestones Regulatory milestones [Member] Represents regulatory milestones. Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Work in process Inventory, Work in Process, Gross Commitments and Contingencies Commitments Contingencies and Guarantees [Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Collaborative Arrangement Collaborative Arrangement [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Consultants and third-party services Consultants And Third Party Services Expense Amount of expense for consultants and third-party services. Employee related expenses Labor and Related Expense Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total costs and expenses Costs and Expenses State State and Local Tax Jurisdiction, Other [Member] Document Quarterly Report Document Quarterly Report Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Contingent payments Contingent Payments Under Agreement Represents additional contingent payments by entities. Adjustment related to prior period sales SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Deferred income tax Deferred Income Taxes and Tax Credits Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Accrued interest receivable, included within prepaid and other assets Interest Receivable, Current Counterparty Name [Domain] Counterparty Name [Domain] Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Corporate bonds and commercial paper Corporate Bond Securities And Commercial Paper [Member] This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds. Medison Medison Pharma Ltd. [Member] Represents Medison Pharma Ltd. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Schedule of Loans Payable, Net Schedule of Debt [Table Text Block] Investment Type [Axis] Investment Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount GAVRETO (pralsetinib) Gavreto [Member] Represents GAVRETO (pralsetinib) product. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Principal payments of term loans Repayments of Long-Term Lines of Credit Restatement Determination Date: Restatement Determination Date [Axis] Issuance of common stock upon exercise of options, net of shares withheld Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Schedule of Prepaid and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Interest expense Interest Expense, Debt Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name All Award Types Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Net income per share Net Income Loss Per Share [Abstract] Net income loss per share abstract. Compensation Amount Outstanding Recovery Compensation Amount Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accrued compensation Increase (Decrease) in Employee Related Liabilities Single reportable segment One Operating Segment [Member] One Operating Segment Provision related to current period sales SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Reported as: Loans Payable, Current and Noncurrent [Abstract] Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Shares under Purchase Plan Employee Stock Employee Stock [Member] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Revenues: Revenues [Abstract] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax 2027 Long-Term Debt, Maturity, Year One Potential payments Collaborative Arrangement Potential Payments Maximum amount of contingent payments under collaborative arrangement. Financial Instruments [Domain] Financial Instruments [Domain] Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Royalty Royalty [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Inventories Increase (Decrease) in Inventories First anniversary of the closing date FirstAnniversaryOfClosingDate [Member] Represents the first anniversary of the closing date. Inventories Inventory, Net Loans payable, net, current portion Loans Payable, Current Minimum [Member] Minimum [Member] Company Selected Measure Name Company Selected Measure Name One month SOFR One Month Secured Overnight Financing Rate (SOFR) [Member] One Month Secured Overnight Financing Rate (SOFR) fostamatinib fostamatinib [Member] Represents fostamatinib. Debt Debt Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Cash payments Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] ocadusertib ocadusertib [Member] RIPK1 inhibitor for the treatment of non-central nervous system (non-CNS) diseases. All Executive Categories All Executive Categories [Member] Common stock Common Stock, Value, Issued Short-term investments Short-Term Investments Diluted (in shares) Weighted-average shares outstanding and common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Accrued research and development Increase (Decrease) in Accrued Research and Development Liability Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid. Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Document Transition Report Document Transition Report EPS Denominator-Basic: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Underlying Securities Award Underlying Securities Amount Government and Other Rebates Government and Other Rebates [Member] Represents government and other rebates. Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Debt term Long-Term Debt, Term Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Income Taxes Income Tax Disclosure [Text Block] Other Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Schedule of Product Revenue Allowance and Reserve Categories SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenues: Revenue from Contract with Customer [Abstract] Specified Development Events Specified Development Events [Member] Represents specified development events. Lease liabilities Increase (Decrease) in Operating Lease Liability Product-by-product Sales Milestone Product-by-product Sales Milestone [Member] Product-by-product Sales Milestone Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Net Income Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Product and Service [Axis] Product and Service [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Total revenues Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Acquisition-related liabilities Asset Acquisition, Contingent Consideration, Liability, Current Other assets Inventory Reported As Other Assets Amount of inventory reported as other assets. All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchase consideration Asset Acquisition, Consideration Transferred Name Forgone Recovery, Individual Name Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] REZLIDHIA Rezlidhia [Member] Represents REZLIDHIA product. Restricted cash Restricted cash [Member] Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Right-of-use assets Increase Decrease Right Of Use Assets Amount of increase or decrease in right-of-use assets. Chargebacks, Discounts and Fees Chargebacks, Discounts and Fees [Member] Represents chargebacks, discounts and fees. Net proceeds from issuance of common stock under equity plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current liabilities: Liabilities, Current [Abstract] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Outstanding borrowing Long-Term Line of Credit Level 1 Fair Value, Inputs, Level 1 [Member] Stock-based compensation expense related to stock-based awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Diluted (in dollars per share) Earnings Per Share, Diluted Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Net income per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Asset Acquisition [Table] Asset Acquisition [Table] Schedule of Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Domestic Tax Jurisdiction Domestic Tax Jurisdiction [Member] Reported as: Inventory And Inventory Reported As Other Assets [Abstract] Inventory And Inventory Reported As Other Assets Cardinal Health, Inc. CardinalHealthInc [Member] Represents Cardinal Health Inc. Strategic collaboration agreement with CONNECT StrategicCollaborationAgreementWithConnect [Member] Represents strategic collaboration agreement with CONNECT, an international collaborative network of pediatric cancer centers. 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Two Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Development and regulatory milestones Development and regulatory milestones [Member] Represents development and regulatory milestones. Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Principal outstanding Long-Term Debt, Gross Accrued compensation Employee-related Liabilities, Current Future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Net income Net income Net income Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Schedule of Fair Value and Gross Unrealized Losses of Our Investments Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Expiration Date Trading Arrangement Expiration Date Other accrued liabilities Other Accrued Liabilities, Current Returns Sales Returns and Allowances [Member] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Reductions in accounts receivable Credit or payments made during the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Net unrealized loss on short-term investments Net change in unrealized loss on short-term investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Option to increase borrowing Line of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option Line of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option Repurchases of common stock in connection with employee tax withholding on RSU vesting Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Base rate Base Rate [Member] Potential tiered royalties Potential Tiered Royalty Percentage The percentage of potential tiered royalties. Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable, net Increase (Decrease) in Accounts Receivable Entity Current Reporting Status Entity Current Reporting Status Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income from operations Operating Income (Loss) Accrued research and development Accrued Research and Development Liability Current Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Line of Credit Line of Credit [Member] Central Nervous System, Specified Development And Regulatory Milestone Central Nervous System, Specified Development And Regulatory Milestone [Member] Central Nervous System, Specified Development And Regulatory Milestone Accumulated deficit Retained Earnings (Accumulated Deficit) Contractual obligations due within one year, not included in financial statements Off Balance Sheet Contractual Obligations Subject To Cancellation Fees Due Within One Year Amount of off-balance sheet contractual obligations subject to cancellation fees to be paid in next fiscal year following current fiscal year. Development Milestones Development Milestones [Member] Represents development milestones. Discounts and allowances Discounts and allowances [Member] Represents discounts and allowances. Cancellation fees under agreements with contract manufacturers Cancellation Fees Under Agreements With Contract Manufacturers Amount of cancellation fees under agreements with contract manufacturers. Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Delivery of drug supply for commercialization One Time Delivery Of Drug Supply For Commercialization [Member] Represents a one-time delivery of drug supply for commercialization. Securities in unrealized loss position for 12 months or less Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Current Fiscal Year End Date Current Fiscal Year End Date Subsequent Event Type [Domain] Subsequent Event Type [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Shares of common stock available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Adjustments to reconcile net income to net cash provided by (used in) operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Sponsored Research and License Agreements Collaborative Arrangement Disclosure [Text Block] Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash Cash [Member] Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Long-term portion of loans payable, net Long-term portion of loans payable, net Loans Payable, Noncurrent Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Revenues Revenue Benchmark [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Variable Rate [Domain] Variable Rate [Domain] Deferred revenue Contract with Customer, Liability Organization and Summary of Significant Accounting Policies Business Description and Accounting Policies [Text Block] Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average shares used in computing net income per share Weighted Average Number of Shares Outstanding, Diluted [Abstract] Contract revenues from collaborations Contract revenues from collaborations [Member] Represents contract revenues from collaborations. All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Strategic collaboration agreement with MDACC Strategic Collaboration Agreement With Mdacc [Member] Represents strategic collaboration agreement with MDACC. Specified Product Launch Events Specified Product Launch Events [Member] Represents specified product launch events. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Financial Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Cost of product sales Cost of Product and Service Sold Schedule of computation of basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Collaboration period Collaboration Term Period of time of collaboration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Subsequent Events [Abstract] Segment Reporting [Abstract] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Costs and expenses: Less: Costs and Expenses [Abstract] Prepaid inventory Prepaid Inventory Amount of asset related to consideration paid in advance for inventory that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Asset Acquisition [Axis] Asset Acquisition [Axis] Contractual obligations due within two to three years, not included in financial statements Off Balance Sheet Contractual Obligations Subject To Cancellation Fees Due In Second And Third Year Amount of off-balance sheet contractual obligations subject to cancellation fees to be paid in second and third fiscal years following current fiscal year. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total Inventory And Inventory Reported As Other Assets Amount of inventory and inventory reported as other assets. Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Revenue reserves and refund liability Revenue Reserves And Refund Liability Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Weighted-average time to maturity Cash Equivalents and Available For Sale Securities, Weighted Average Maturity Period Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities. Subsequent Events Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Remainder of 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Raw Materials Inventory, Raw Materials, Gross Asset acquisition, expected price Asset Acquisition, Price of Acquisition, Expected Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table] Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table] Schedule of cash and cash equivalent balances, excluding any restricted cash balances, and available-for-sale securities. Total liabilities Liabilities Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Schedule of Revenues From Product Sales Disaggregated by Customers Disaggregation Of Revenue By Customer [Table Text Block] Tabular disclosure of disaggregation of revenue by customer. Statement [Line Items] Statement [Line Items] Variable Rate [Axis] Variable Rate [Axis] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock Common Stock [Member] Fair Value Debt Securities, Available-for-Sale Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Achievement of certain near-term regulatory milestone Achievement of certain near-term regulatory milestone [Member] Represents achievement of a certain near-term regulatory milestone. Cencora, Inc. CencoraInc [Member] Represents Cencora Inc. Dilutive effect of stock options, RSUs and shares under Purchase Plan (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment